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A B S T R A C T
OspC performs essential functions during the enzootic cycle of the Lyme disease (LD) spirochetes. In this
study, the speciﬁcity of antibody (Ab) responses to OspC was proﬁled to deﬁne the antigenic determi-
nants during infection and after vaccination. Several OspC variants or ‘types’ were screened with serum
from SNAP4Dx C6 positive dogs and with serum from rabbits hyperimmunized with OspC proteins. The
OspC type-speciﬁc nature of the Ab response revealed that variable domains of OspC are immunodominant
during infection and upon vaccination. To assess the potential of OspC to elicit Ab in the context of a
bacterin vaccine, OspC production in strains cultivated in vitro was assessed. Immunoblot and indirect
immunoﬂuorescent antibody analyses demonstrated that production is low and that only a subset of cells
actively produces OspC in vitro, raising questions about the potential of bacterin vaccines to stimulate
signiﬁcant anti-OspC Ab responses. The speciﬁcity of the OspC Ab response in experimentally infected
mice over time was assessed to determine if domains shielded in the OspC homodimer become acces-
sible and stimulate Ab production as infection progresses. The results demonstrate that the OspC Ab response
remains focused on surface exposed variable regions of the protein throughout infection. In contrast to
some earlier studies, it is concluded that conserved domains of OspC, including the C7 or C10 domain,
do not elicit signiﬁcant Ab responses during infection or upon vaccination. Collectively, the results in-
dicate that OspC diversity must be considered in vaccine design and in the interpretation of diagnostic
assays that employ OspC as a diagnostic antigen.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The incidence of Lyme disease (LD) in dogs and human beings
is increasing and endemic regions are expanding in many regions
of North America and Europe (Mead et al., 2011; Tseng et al., 2015;
Sykes and Makiello, 2016). The primary etiological agent of LD in
North America is Borrelia burgdorferi (Burgdorfer et al., 1982; Benach
et al., 1983) while in Europe and Asia, B. burgdorferi, B. garinii, B.
bavariensis, and B. afzelii are themain species associated with disease
(Baranton et al., 1992;Marconi and Garon, 1992;Margos et al., 2013).
We refer to this group of bacterial species collectively as the ‘LD spi-
rochetes’. LD is transmitted among its diverse mammalian reservoirs
and to its incidental hosts (human beings and dogs) by Ixodes ricinus
complex ticks (Barbour and Hayes, 1986). The number of counties
in the USA where I. scapularis or I. paciﬁcus populations are now es-
tablished has risen by 49% since 1996 (Eisen et al., 2016). In 2014,
the Centers for Disease Control and Prevention reported that the
number of LD cases each year in humans is between 300,000 and
450,000 (Hinckley et al., 2014). Data compiled by the Companion
Animal Parasitic Council (CAPC) indicate moderate to high risk for
LD in dogs in much of the Eastern half of the US and Southern
Canada. In 2015, 250,880/4,062,155 (6.2%) tested dogs in the USwere
antibody (Ab) positive for LD. As detailed by CAPC1, these numbers
represent about 30% of the total, bringing the probable number of
Ab positive tests in dogs in 2015 to approximately 800,000.
OspC, an essential virulence factor of the LD spirochetes, has been
a major focus of efforts to develop new LD vaccines and diagnostic
assays (Grimm et al., 2004; Tilly et al., 2006; Earnhart et al., 2010).
OspC production is stimulated in feeding ticks and maintained
through early stage infection in mammals, in which it is an
immunodominant antigen (Dressler et al., 1993; Fung et al., 1994;
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Fingerle et al., 1995; Schwan et al., 1995; Gilmore and Piesman, 2000;
Pal et al., 2004). The high level expression of OspC in fed ticks and
mammals and its antigenicity during early infection are proper-
ties that support the use of OspC (or OspC derived proteins) in
vaccines and as a diagnostic antigen (Schwan, 2003; Earnhart et al.,
2005; Baum et al., 2014). However, OspC is a highly variable protein
with ~30 distinct variants or ‘types’ having been deﬁned (Brisson
and Dykhuizen, 2004; Earnhart and Marconi, 2007c; Brisson et al.,
2012; Rhodes et al., 2013). OspC types are differentiated by letter
designations (e.g. type A, type B).
Different conclusions have been reached regarding the identity
of the antigenic determinants of OspC that stimulate Ab responses
during infection or upon vaccinationwith either LD bacterins or re-
combinant OspC based proteins (Earnhart et al., 2005; Callister et al.,
2015). Understanding the antigenic structure of OspC is essential
for the translational applications indicated above. Studies in mice
and humans suggest that sequence variation, particularlywithin the
coding sequenceof the variable loop5 (L5) andαhelix 5 (H5) epitopes
of OspC, leads to highly speciﬁc Ab responses during infection
(Earnhart et al., 2005; Buckles et al., 2006; Earnhart and Marconi,
2007a, 2007b; Baum et al., 2016). Other studies implicate con-
serveddomains of OspC, such as theC7domain, as immunodominant
(Mathiesen et al., 1998b; Gilmore and Mbow, 1999). C7, which has
also been referred to as the C10 or pepC10 domain, consists of the
C-terminal residues of OspC (Mathiesen et al., 1998a; Wang et al.,
1999; Earnhart et al., 2014). In this paper, we use the designation
C7/C10 for this domain. It has also been suggested that OspC pro-
ductionpatternsmaybeuniquely different in dogs compared to other
mammals (Lovrich et al., 2007; Callister et al., 2015).
In this study, we assessed the speciﬁcity and evolution of IgG
responses to OspC in the context of natural canine infection, ex-
perimental infection inmice and upon hyperimmunization of rabbits
with recombinant OspC proteins. In addition, since B. burgdorferi
cell lysates are the basis for LD bacterin vaccines, we also assessed
the production levels of OspC during in vitro cultivation. The results
of this study highlight the importance of considering OspC pro-
duction levels and diversity in vaccine design and diagnostic assay
interpretation.
Materials and methods
Bacterial strains, cultivation and serum samples
All strains (Table 1) were cultivated in BSK-Hmedia with 6% rabbit serum (Sigma-
Aldrich; 37 °C; 5% CO2) with 100× antibiotic mix (phosphomycin, rifampicin and
amphotericin B; Sigma-Aldrich) as required. Growth was monitored by dark ﬁeld
microscopy. Canine patient serum samples were obtained on a fee for service basis.
Information on each dog is presented in Table 2. All dogs were SNAP4Dx (IDEXX)
positive for C6 Ab. A subset that was OspC Ab positive, as determined by ELISA (data
not shown) using several previously developed OspC epitope based chimeric pro-
teins referred to as chimeritopes (Earnhart and Marconi, 2007b) was selected for
further analyses.
Murine studies
Mid-log phase B. burgdorferi strains B31MI, LDP56 and LDP84 cells were recov-
ered by centrifugation, washed with phosphate buffered saline (PBS) and 1 × 105 cells
were needle inoculated into C3h-HeJ mice (n = 5 per group; Jackson Laboratories)
(McDowell et al., 2001). Blood was collected from B31MI infected mice at weeks 0,
2, 4, 6 and 12 by tail nick. Blood was collected from LDP56 and LDP84 infected mice
at weeks 0 and 4. Mice were euthanazed at either week 4 or 12 and blood was col-
lected by cardiac puncture. Serum was harvested by standard methods. All animal
experiments were conducted following the Guide for the Care and Use of Labora-
tory Animals (8th edition) and in accordance with protocols peer reviewed and
approved by VCU Institutional Animal Care and Use Committees and/or the Statens
Serum Institute.
Generation of OspC recombinant proteins and antiserum
To generate OspC proteins (types A through N), each gene (minus the leader
peptide) was PCR ampliﬁed (Pfu polymerase) from the appropriate isolate (Table 1).
The PCR primers (Earnhart et al., 2005, 2010) were designed for ligase independent
cloning (LIC) into the pET46Ek-LIC (Novagen). The resulting plasmids were used to
generate recombinant proteins in E. coli (Miller et al., 2012). The His-tagged pro-
teins were puriﬁed using a Ni-Aﬃnity column and an AKTA puriﬁcation system (GE
Healthcare) (Miller et al., 2012). Protein concentrations were determined using the
BCA Protein Assay Kit (Thermo Scientiﬁc). Antiserum to each puriﬁed protein was
generated in New Zealand white rabbits (Statens Serum Institute) (Theisen, 1996).
Dot blot, SDS–PAGE and immunoblot analyses
Immunoblot strips harboring the puriﬁed OspC proteins were generated using
the Bio-Dot Apparatus (Bio-Rad). Protein (100 ng; 1× Tris buffered saline, TBS) was
added to each well and the proteins were adhered to the nitrocellulose mem-
branes under gravity ﬂow. After washing three times with TBS, the membranes were
removed and prepared for immunoblot analysis as described below. All mem-
branes were stained with MemCode Reversible Protein Stain Kit (Thermo Scientiﬁc).
For sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE), re-
combinant proteins (500 ng) or B. burgdorferi B31MI cell lysate (0.33 optical density
units at 600 nm, OD600, per 100 μL SDS–PAGE solution) was boiled, sonicated and
fractionated on Any-kD precast Criterion gels (BioRad). One set of gels was stained
with Coomassie brilliant blue and others were used to transfer proteins to
polyvinylidene ﬂuoride (PVDF)membranes using the Trans-Blot Turbo Transfer System
(BioRad) and standard methods.
For the immunoblot analyses, nonspeciﬁc binding was blocked with 1× PBS con-
taining 0.2% Tween-20 with 5% non-fat dry milk (PBSTM) for 1 h at room temperature
(RT). The membranes were probed with canine or rabbit serum (1:500 or 1:15,000
in PBSTM, respectively) and incubated for 1 h at RT. Blots were washed three times
with PBST and rabbit anti-dog IgG or goat anti-rabbit IgG conjugated to horserad-
ish peroxidase (1:40,000 in PBSTM; Pierce) was added for 1 h at RT. After washing,
bound IgG was detected using the SuperSignal West Pico Western blotting sub-
strate (BioRad).
Indirect immunoﬂuorescence assays
Indirect immunoﬂuorescence assays (IFAs) were conducted as previously de-
scribed (Earnhart et al., 2010). Cells in PBS were placed on Superfrost Plus slides
(Fisher Scientiﬁc), air dried, permeabilized with acetone, air dried and then non-
speciﬁc binding blocked by the addition of PBSTB (PBST with 3% bovine serum
albumin). Slides were screened with mouse pre-immune serum, anti-OspC type A
or anti-OspA antiserum (1:25,000 in PBSTB; 30 min), washed with PBST and bound
IgG was detected with Alexa Fluor 568-conjugated goat anti-mouse IgG (Molecu-
lar Probes). The slides were washed, coverslips mounted (ProLong Gold; Molecular
Probes), and bound Ab was detected by ﬂuorescence microscopy (BX51; Olympus).
Table 1







B31-B31MI A A clonal population derived from isolate B31
which was originally obtained from an Ixodes
scapularis tick (NY, USA). The genome sequence of
the B31 parental strain has been sequenced (Fraser
et al., 1997).
LPD73 B Human blood – NY, USA (Earnhart et al., 2005)
LPD84 C Human blood – NY, USA (Earnhart et al., 2005)
LDP116 D Human blood – NY-USA (Earnhart et al., 2005)
DRI-03a H Tissue biopsy from a purpose bred beagle infected
by tick infestation with Ixodes scapularis ticks from
RI, USA; clonal population (clone a) obtained by
sub-surface plating (Rhodes et al., 2013)
B331 I Human blood, NY, USA
LDP89 K Human blood, NY, USA (Earnhart et al., 2005)
Veery M Veery bird, CT, USA
LDP56 A Human blood, NY, USA (Earnhart et al., 2005)
DRI40h F Tissue biopsy from a purpose bred beagle infected
by tick infestation with Ixodes scapularis ticks from
RI, USA; clonal population (clone h) obtained by
sub-surface plating (Rhodes et al., 2013)
LDP74 K Human blood, NY, USA (Earnhart et al., 2005)
LDP63 N Human blood, NY, USA (Earnhart et al., 2005)
B31ΔospC A ospC gene deletion mutant derived from strain
B31MI (Earnhart et al., 2010)
B31-HE-OspC A Provided by Dr. Patti Rosa (NIH); derived from
parental strain B31-5A3; designated in original
publication as ospCK1/pBSV2G-ospC (Tilly et al.,
2006); encodes a second copy of the ospC gene on
plasmid pBSV2G which also encodes gentamicin
resistance (genR)
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Mouse anti-OspA served as a positive control, since OspA is expressed during in vitro
cultivation. Pre-immune serum served as a negative control. Cells were also visu-
alized by dark-ﬁeld microscopy.
Results
Analysis of antibody responses to OspC in naturally infected dogs and
in rabbits hyperimmunized with OspC proteins
To assess IgG responses to OspC in infected dogs, serum from 25
C6 Ab positive client owned dogs (SNAP4Dx) was screened against
14 OspC type proteins that represent the major variants found in
North America (Earnhart and Marconi, 2007c; Cerar et al., 2016).
All dogs were seropositive for one or more OspC variants (Table 2;
Fig. 1). Five reacted with a single OspC type, 13 reacted with two to
ﬁve types and seven reacted with >10 types. The selective recog-
nition of different OspC type proteins indicates that the
immunodominant epitopes of OspC must reside within variable
domains as opposed to conserved regions, suchas theC7/C10domain.
To assess the speciﬁcity of IgG responses to divergent OspC pro-
teins, rabbits were hyperimmunized with OspC type A, B, C, D, H or
K protein. Dot blot analyses revealed that immunization elicits OspC
type speciﬁc Ab (Table 3), supporting the data above, indicating that
it is the variable domains of OspC, such as the L5 and/or H5 epitopes,
which are immunodominant. These results are also consistent with
earlier studieswhich demonstrated that immunization ofmicewith
a single OspC protein elicits an Ab response with a narrow protec-
tive range (Gilmore et al., 1996; Bockenstedt et al., 1997).
Analysis of OspC production levels by B. burgdorferi during
in vitro cultivation
OspC concentration in a bacterin should be proportional to its
contribution in eliciting bactericidal Ab responses in vaccinated
animals. Since bacterins are produced using in vitro cultivated spi-
rochetes, we assessed OspC production levels in several cultivated
strains. SDS–PAGE gels of cell lysates were stained or immunoblotted
and screened with anti-OspC type A antiserum (Fig. 2A). Strain B31-
HE-OspC served as a positive control (Tilly et al., 2006). Stained gels
and immunoblots revealed low or variable levels of OspC produc-
tion in B31, LDP56 and LDP74 strains (types A and K OspC,
respectively). While variable staining of OspC with CBB stain
(Alverson et al., 2003) could contribute to the interpretation of these
data, we conﬁrmed through staining of SDS–PAGE gels loaded with
known amounts of each OspC protein that staining was equal (data
not shown). As expected, high levels of OspC were detected in the
B31-HE-OspC strain and no OspCwas detected in B31ΔospC (Earnhart
et al., 2010). Strains LDP84 and DRI40h (OspC types C and F, re-
spectively) (Earnhart et al., 2005; Rhodes et al., 2013) were weakly
reactive with the anti-OspC type A antiserum due to both low ex-
pression (no visible OspC band upon staining) and weak recognition
by anti-type A OspC antiserum. While a visible OspC band was ob-
served in the DRI40h cell lysate upon staining, the protein was only
weakly reactive with the anti-OspC type A antiserum. Analysis of
OspC expression at the population level using IFAs revealed that only
a subset of B31 cells produces OspC during cultivation, whereas all
B31-HE-OspC cells produced OspC (Fig. 2B). Immunoblot and IFA
analyses of additional B. burgdorferi strains also revealed low level,
sub-population dependent OspC production (data not shown). In
contrast to OspC, OspA, which is known to be produced at high levels
in vitro, was produced by all cells.
Table 2





Recombinant OspC types/scoring of immunoreactivitya Number of OspC types
detected by infection serum
A M F C D H B I K N E G J L
PI Beagle Unknownb 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SP2 Labrador retriever DC 3 2 1 1 1 1 0 0 2 0 1 2 3 0 10
DB Golden retriever VA 4 2 3 3 3 3 4 3 3 3 3 3 3 3 14
MT Yorkshire terrier OH 1 1 3 0 0 3 0 0 0 0 1 0 0 0 5
BS Golden retriever NC 4 1 1 2 1 1 0 0 2 2 3 2 2 1 12
TB English setter VA 0 2 2 0 0 0 0 0 0 0 0 1 0 0 3
SW Golden retriever VA 1 0 0 0 0 1 0 0 0 0 0 0 0 0 2
PB Newfoundland ME 0 0 2 0 0 2 0 0 0 0 0 3 0 0 3
CTR Beagle MI 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1
GP Bouvier des Flandres MD 3 3 2 4 2 2 1 1 0 1 1 2 1 0 12
BM Mixed breed MD 2 2 0 2 0 2 0 0 0 2 0 0 0 0 5
LD Lhasa Apso CT 0 0 0 0 0 0 0 0 0 0 0 3 0 0 1
TO Labrador retriever VA 2 0 0 0 0 0 0 2 0 0 0 0 0 0 2
HS Beagle NC 4 4 3 3 4 3 4 4 4 4 4 4 3 4 14
HP Unknown Unknownb 2 2 0 0 0 0 1 1 2 2 2 3 1 1 10
CTZ Mixed breed VA 0 0 0 0 0 3 0 0 2 0 0 0 0 0 2
AH Mixed breed PA 2 0 0 0 0 0 0 0 0 0 2 0 0 0 2
SK Mixed breed IL 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1
TJ Great Dane OH 0 0 0 0 0 0 0 0 0 0 1 1 0 0 2
SM Retriever MD 3 0 3 3 3 3 3 2 3 0 2 3 3 3 12
JP Golden retriever MD 0 0 0 0 0 3 0 1 0 0 2 4 0 0 4
BH Mixed breed VA 3 0 0 0 0 0 0 0 0 2 0 1 0 0 3
AS Mixed breed OH 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1
CT Mixed breed VA 0 0 0 0 0 0 0 0 0 0 0 3 0 0 1
BH Border collie AR 0 0 0 2 0 1 0 3 0 0 0 0 0 0 3
TT Mixed breed NY 2 3 0 0 2 2 0 0 0 0 0 3 0 0 5
a Reactivity on the dot blots was scored using a scale of 0–4, with 0 indicating no Ab detection and 4 indicating strong Ab detection.
b The designation ‘unknown’ indicates that information about either the breed or state of origin was not available.
Table 3
Speciﬁcity of OspC Ab responses in hyperimmunized rabbits.
Serum identiﬁcation B N C D H K A
Anti-OspC type B + − − − − − −
Anti-OspC type C − − ++ − − ++ ++
Anti-OspC type D − − − ++ − − −
Anti-OspC type H − − − − ++ − −
Anti-OspC type K − − − − − ++ +
Anti-OspC type A − − − − − − ++
Rabbit pre-immune − − − − − − −
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Speciﬁcity of the anti-OspC antibody response over the course of
infection in mice
The evolution of the speciﬁcity of the OspC response during in-
fection was assessed by screening OspC proteins with serum
harvested at 0, 2, 4, 6 and 12 weeks frommice infected with B31MI
(Fig. 3). IgG to type A OspC was detected after week 2, with levels
increasing out to week 12. While the Ab response was predomi-
nantly directed at OspC type A, and remained so throughout
infection, weak cross reactivity with some other OspC types was
observed. The Ab response in mice infected with LDP56 at week 4
was also type-speciﬁc. In contrast, Ab frommice infected with LDP84
(type C OspC) detected OspC types C, M, A and H. Comparative anal-
ysis of the L5 and H5 epitope sequences from OspC types C, M, A
and H revealed that segments of the H5 epitope are conserved among
OspC types M and C (85% amino acid identity over a 39 amino acid
residue stretch), with the sequence differences localized within the
N and C-terminal portions of the epitope. These differences would
not be expected to interfere with cross reactivity of Ab against the
type M and C H5 epitopes. In contrast, amino acid difference scat-
tered throughout the H5 epitopes of OspC types A, C and H (69%
identity) would presumably prevent Ab cross reactivity among these
OspC types.
Discussion
Analyses of anti-OspC Ab responses in naturally infected dogs
using divergent OspC proteins as detection antigens demon-
strated signiﬁcant variation in Ab responses among individual
animals. Serum Ab from most infected dogs recognized a limited
and variable subset of themost prevalent OspC types of North Amer-
ican LD isolates (Brisson and Dykhuizen, 2004; Earnhart andMarconi,
2007c; Strle et al., 2011). This observation suggests that the dom-
inant immuno-stimulatory determinants of OspC reside within
variable domains. Others have postulated that conserved domains,
speciﬁcally the C7/C10 domain, are immunodominant (Mathiesen
et al., 1998a; Bacon et al., 2003; Porwancher et al., 2011; Arnaboldi
et al., 2013). However, if that were the case during canine infec-
tion, then all OspC variants screened with infection serum would
be immunoreactive, regardless of the OspC type identity of the in-
fecting strain(s). Additional evidence arguing against a signiﬁcant
contribution of C7/C10 in OspC Ab responses in canines came from
allelic exchange replacement studies (Earnhart et al., 2014). Re-
placement of the native ospC of B. burgdorferi B31 with an ospC that
lacks the coding sequence for the C7/C10 domain had no effect on
OspC Ab titers elicited during infection in mice. The weak antige-
nicity of the C7/C10 domain may indicate that it is not surface
exposed on the OspC dimer. OspC atomic structures revealed C7/
C10 domain to be structurally unordered and its placement within
OspC has not been deﬁned (Eicken et al., 2001; Kumaran et al., 2001).
Type-speciﬁc responses to OspC were also observed in rabbits
immunized with different OspC type proteins. This observation was
surprising, since onemight expect buried ormasked epitopes hidden
in the context of the OspC dimer in viable cells to be accessible in
recombinant proteins. The type-speciﬁc responses might reﬂect the
highly stable and rigid structure of the OspC homodimer (Eicken
et al., 2001; Kumaran et al., 2001). It is noteworthy that the buried
interface of the dimer constitutes 22% of the total surface accessi-
ble area of each monomer (Kumaran et al., 2001). The data above
support the notion that a single OspC protein would be ineffective
in stimulating a broadly protective Ab response.
It has been suggested that OspC present in bacterin vaccines may
stimulate bactericidal Ab production (LaFleur et al., 2010). However,
OspC production during in vitro cultivation has been demon-
strated by several research groups to be variable, low level and
inﬂuenced by temperature (Schwan et al., 1995; Yang et al., 2000;
Ohnishi et al., 2001; Ramamoorthy and Scholl-Meeker, 2001;
Alverson et al., 2003; Mulay et al., 2009). In this study, IFA and
immunoblot analyses were employed to assess OspC production
levels at the population level and among strains under standard cul-
tivation conditions (37 °C; BSK-H complete media). Immunoblotting
revealed relatively low expression and IFA analyses demonstrated
that only a fraction of cells in culture produce OspC. Hence, in the
context of a bacterin vaccine, OspC constitutes a minor fraction of
the total protein content. This may explain the low level of OspC
targeting bactericidal Ab activity detected in the serum of dogs vac-
cinated with some LD bacterins (Lovrich et al., 2007). LaFleur et al.
sought to compensate for this through the use of a two strain bac-
terin consisting of strain S-1-10 and an ospAB- strain (LaFleur et al.,
2010). Strains that are unable to produce OspA either as a result
of plasmid loss or genetic manipulation tend to produce more OspC
than their wild-type counterparts (He et al., 2008; Srivastava and
de Silva, 2008). However, it remains to be determined if bacterins,
Fig. 1. The IgG response to OspC during natural infection with Borrelia burgdorferi
in client owned dogs is OspC type speciﬁc. Fourteen recombinant OspC proteins were
generated, puriﬁed and spotted onto nitrocellulose membranes using a dot blotter
as detailed in the text. The type identity of each protein is indicated above the top
panel (representative data are shown for six recombinant OspC proteins). The dot
blot strips were screened with canine serum (indicated by an identiﬁcation desig-
nation, ID) diluted 1:500, as detailed in the methods. Serum from an infection free
dog (SNAP4Dx and OspC Ab negative; normal canine serum, NCS) served as a neg-
ative control. Twenty-ﬁve SNAP4Dx positive dogs were screened (representative data
are shown with the complete data set presented in Table 2). To verify similar loading
of each protein on the blot, one dot blot was stainedwithMemCode Reversible Protein
Stain Kit (Thermo Scientiﬁc). The stained blot is indicated as ‘stain’.
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such as that described above, do in fact harbor elevated amounts
of OspC.
To determine if the Ab response to OspC remains type-speciﬁc
as infection progresses, serum was collected over time from mice
infected with B31MI (type A OspC) and used to screen a panel of
eight OspC type proteins. Ab speciﬁcity remained largely speciﬁc
for type A OspC, with only minor cross reactivity with other OspC
proteins. Hence, even with cell turnover during infection which
would liberate OspC from the membrane, conserved portions of the
protein do not appear to elicit signiﬁcant Ab responses.
The speciﬁcity of the OspC Ab response has implications for
vaccine and diagnostic assay development. Based on the data pre-
sented here and in earlier studies (Earnhart andMarconi, 2009; Baum
et al., 2014), the broad protective capability of OspC based vac-
cines is clearly enhanced by the inclusion of multiple epitopes
derived from diverse OspC type proteins. Consistent with earlier lit-
erature, broad protection cannot be achieved using a single OspC
protein or cocktail of OspC proteins (Earnhart and Marconi, 2009).
A chimeric OspC epitope protein, referred to as a ‘chimeritope’
(Earnhart and Marconi, 2007b; Earnhart et al., 2007; Marconi and
Earnhart, 2010), has been developed and is a central component
of Vanguard crLyme vaccine (Zoetis)2. OspC chimeritopes that consist
almost entirely of L5 and H5 epitopes from diverse OspC variants
have been demonstrated to elicit Abwith bactericidal activity against
diverse strains (Earnhart and Marconi, 2007b; Earnhart et al., 2007).
Hence, it can be concluded that the C7/C10 domain is not strictly
required for stimulating bactericidal Ab. Consistent with this, Lovrich
et al. (2007) concluded that, while C7/C10 may stimulate bacteri-
cidal Ab in human beings, it does not in dogs.
The data presented here also suggest that a single OspC variant
is insuﬃcient to serve as a reliable diagnostic antigen; for example,
as shown in Fig. 1, canine TB is clearly seropositive for OspC types
F and M. However, canine TB was negative or weakly positive for
OspC types A, C, D and H. Hence, the use of an OspC variant other
than types F and M as a diagnostic antigen would have resulted in
a false negative diagnosis of dog TB. The importance of a multi-
valent approach can also be gleaned from several published studies
that have assessed OspC as a diagnostic antigen. In one study where
a single OspC protein (derived from strain 50772) served as a di-
agnostic antigen, a positive Ab response to OspC was detected in
only 3/24 beagles infected by tick infestation, leading the authors
to conclude that OspC is unreliable as a diagnostic antigen (Callister
et al., 2015). Another study used cell lysates of strain 297 (type E
OspC) as the immobilized antigen to assess Ab responses to OspC
in infected dogs (Callister et al., 2015). While all dogs assessed in
that study were culture positive for the LD spirochetes, only 1/14
was reported to be OspC Ab positive. In light of the fact that OspC2 See: www.zoetisus.com/products/dogs/vanguard-crlyme.
Fig. 2. OspC is expressed at low and variable levels during in vitro cultivation. To assess OspC expression levels during in vitro cultivation, cell lysates of Borrelia burgdorferi
strains were separated by SDS–PAGE and then stained or immunoblotted. The strains analyzed are indicated above each panel and are described in detail in Table 1. Panel
A is an image of a gel stained with Coomassie brilliant blue and panel B is an immunoblot screened with mouse anti (α)-OspC (type A) antiserum with HRP conjugated goat
anti-mouse IgG diluted 1:15,000 and 1:40,000, respectively. Molecular weight (MW) standards are indicated. Panel B presents the results of indirect immunoﬂuorescent
assay (IFA) analyses of B. burgdorferi B31 and B. burgdorferi B31-HE-OspC (as labeled). The cells were screened with anti-OspA and anti-OspC type A antiserum, as indi-
cated. The secondary is Alexa Fluor 568-conjugated goat anti-mouse IgG. The cells were visualized by ﬂuorescence microscopy using a rhodamine ﬁlter. The corresponding
dark ﬁeld microscopy images are shown.
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is required for infection and is a proven early antigen, the lack of
detection of an anti-OspC response in the aforementioned studies
may instead be due to the use of a single OspC variant as the di-
agnostic antigen.
Conclusions
The antigenic properties of OspC suggest that careful consider-
ation must be given to OspC diversity in the development of LD
vaccines and diagnostic assays. One attractive approach eluded to
above to address OspC diversity is the use of OspC chimeritopes,
which have the potential to elicit broadly protective Ab responses
that can both inhibit spirochete transmission from ticks to mammals
and kill spirochetes that enter mammals. The potential exists to
extend this technology to development of veterinary and human
LD diagnostic antigens as well as in the development of a human
LD vaccine.
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